A number of studies have reported that D-cycloserine (DCS), a partial agonist of the N-methyl-D-aspartate glutamate receptor, can facilitate the loss of conditioned fear if it is administered during an extinction trial. Here we examine the effects of DCS injected into the hippocampus or amygdala on extinction of context-evoked freezing after contextual fear conditioning in C57BL/6 mice. We find that DCS administered prior to an extinction session decreased freezing from the outset of the session regardless of which brain region was targeted. Retention tests revealed opposite effects on fear expression despite identical behavioral treatments: intra-hippocampal DCS inhibited fear expression while intra-amygdala DCS potentiated fear expression. Following post-extinction session injections of DCS, we found a similar though less pronounced effect. Closer inspection of the data revealed that the effects of DCS interacted with the behavior of the subjects during extinction. Intra-hippocampal injections of DCS enhanced extinction in those mice that showed the greatest amount of within-session extinction, but had less pronounced effects on mice that showed the least within-session extinction. Intra-amygdala injections of DCS impaired extinction in those mice that showed the least within-session extinction, but there was some evidence that the effect in the amygdala did not depend on behavior during extinction. These findings demonstrate that even with identical extinction trial durations, the effects of DCS administered into the hippocampus and amygdala can heavily depend on the organism's behavior during the extinction session. The broader implication of these findings is that the effects of pharmacological treatments designed to enhance extinction by targeting hippocampal or amygdalar processes may depend on the responsivity of the subject to the behavioral treatment.
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A number of studies have reported that D-cycloserine (DCS), a partial agonist of the N-methyl-D-aspartate glutamate receptor, can facilitate the loss of conditioned fear if it is administered during an extinction trial. Here we examine the effects of DCS injected into the hippocampus or amygdala on extinction of context-evoked freezing after contextual fear conditioning in C57BL/6 mice. We find that DCS administered prior to an extinction session decreased freezing from the outset of the session regardless of which brain region was targeted. Retention tests revealed opposite effects on fear expression despite identical behavioral treatments: intra-hippocampal DCS inhibited fear expression while intra-amygdala DCS potentiated fear expression. Following post-extinction session injections of DCS, we found a similar though less pronounced effect. Closer inspection of the data revealed that the effects of DCS interacted with the behavior of the subjects during extinction. Intra-hippocampal injections of DCS enhanced extinction in those mice that showed the greatest amount of within-session extinction, but had less pronounced effects on mice that showed the least within-session extinction. Intra-amygdala injections of DCS impaired extinction in those mice that showed the least within-session extinction, but there was some evidence that the effect in the amygdala did not depend on behavior during extinction. These findings demonstrate that even with identical extinction trial durations, the effects of DCS administered into the hippocampus and amygdala can heavily depend on the organism's behavior during the extinction session. The broader implication of these findings is that the effects of pharmacological treatments designed to enhance extinction by targeting hippocampal or amygdalar processes may depend on the responsivity of the subject to the behavioral treatment.
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Introduction
The attenuation of a conditioned fear response in rodents via extinction, the process of repeated re-exposure to a conditioned fear-evoking stimulus, is a valuable model of treatments for clinical cases of anxiety and fear in humans. Indeed, treatments for fear and anxiety disorders in humans frequently involve exposure therapies that draw heavily from the findings of extinction research in rodents (Hofmann, 2008; Milad & Quirk, 2012; Milad, Rauch, Pitman, & Quirk, 2006) . Although exposure-based therapies in clinical populations can be highly effective in reducing fear and anxiety levels in the short-term, patients often remain vulnerable to relapse in the long-term (Rachman, 1989) . This clinical phenomenon is consistent with the well-established observation that extinction in animals involves new learning processes that largely leave the original fear memory intact and susceptible to spontaneous recovery (Rescorla, 2004 ), renewal (Bouton, 2002 ) and reinstatement (Rescorla & Heth, 1975) . As such, one converging challenge of basic research on extinction in animals and exposure-based therapies in humans is the development of procedures that result in relatively fast and persistent inhibition of abnormal fear responses.
One way to enhance the persistence of fear inhibition is to administer pharmacological agents that target cellular and molecular processes that may be involved in extinction memory formation (e.g., Davis, 2011; Ganasen, Ipser, & Stein, 2010; Griebel & Holmes, 2013; Hofmann, Smits, Asnaani, Gutner, & Otto, 2011; Lattal & Wood, 2013) . A cellular target of particular interest is the N-methyl-D-aspartate (NMDA) glutamate receptor, which supports the process of long-term synaptic potentiation thought to underlie the new associative learning that occurs during extinction (Myers & Davis, 2007; Orsini & Maren, 2012) . Indeed, a large body of literature indicates that administration of the partial NMDA agonist D-cycloserine (DCS) in conjunction with exposure therapy facilitates reductions in abnormal fear and anxiety in human clinical populations (Difede et al., 2013; Guastella et al., 2008; Hofmann et al., 2006; Nave, Tolin, & Stevens, 2012; Ressler et al., 2004) . Early findings in rodents have also demonstrated that DCS
